Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a proven and documented diagnosis of non-cystic fibrosis idiopathic or post pneumonic bronchiectasis~* Stable pulmonary status and stable regimen of standard treatment at least for the past 30 days~Exclusion Criteria:~* Forced Expiratory Volume 1 \< 35% or \> 80%~* Allergic bronchopulmonary aspergillosis~* Immunodeficiency disease requiring immunoglobulin replacement~* Inflammatory bowel disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ciprofloxacin Inhale (BAYQ3939) (Type: EXPERIMENTAL): 32.5 mg ciprofloxacin hydrated corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation Powder twice daily
- Placebo (Type: PLACEBO_COMPARATOR): Inhalation of matching placebo twice a day

Based on this trial design, predict the completion outcome and termination type (if applicable).